Cargando…

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury

BACKGROUND: In patients with multiple myeloma (MM) free light chain-induced cast nephropathy is a serious complication associated with poor survival. High-cut-off (HCO) hemodialysis can reduce the amount of serum free light chains (sFLC), but data on its impact on clinical outcome is limited and con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steiner, N., Abdel Hamid, A., Kronbichler, A., Neuwirt, H., Myslivecek, M., Kollar, M., Lachmanova, J., Rysava, R., Hruskova, Z., Spicka, I., Willenbacher, W., Nachbaur, D., Wolf, D., Tesar, V., Gunsilius, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357738/ https://www.ncbi.nlm.nih.gov/pubmed/33382447 http://dx.doi.org/10.1007/s40620-020-00939-2

Ejemplares similares

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report
por: Gauckler, Philipp, et al.
Publicado: (2020)

Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study
por: Frausová, Doubravka, et al.
Publicado: (2016)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
por: Steiner, Normann, et al.
Publicado: (2023)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA – associated vasculitis
por: Satrapova, Veronika, et al.
Publicado: (2023)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?
por: Steiner, N., et al.
Publicado: (2019)

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Hajek, Roman, et al.
Publicado: (2020)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
por: Richardson, Paul G., et al.
Publicado: (2020)

Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis
por: Hladinova, Z., et al.
Publicado: (2015)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
por: Sonneveld, P, et al.
Publicado: (2022)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
por: Mateos, Maria V., et al.
Publicado: (2021)

Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report
por: Klanova, Magdalena, et al.
Publicado: (2012)

Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy
por: Tesar, Vladimir, et al.
Publicado: (2021)

Complement Inhibition in ANCA-Associated Vasculitis
por: Tesar, Vladimir, et al.
Publicado: (2022)

Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up
por: Pesickova, Satu Sinikka, et al.
Publicado: (2015)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hqdqacsg1kph00lsv442vkkipk